太平洋生物科学 PACB
$2.26 −$0.18 (-7.20%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $2.25 -0.14%
开盘$2.43
昨收$2.43
当日区间$2.24 – $2.54
成交量9.56M
市值$705.65M
市盈率（TTM）–
股息率–
财报
财报日平均波动±9.1%近16次财报
收涨次数6 / 1638% 的概率
最佳反应+25.0%
最差反应-14.5%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 5 Aug 2026 | After Market | – | -10.38% | – |
| 2026/Q1 | 7 May 2026 | After Market | ±14.5% | -14.55% | 超出定价预期 |
| 2025/Q4 | 12 Feb 2026 | After Market | ±19.0% | -7.07% | 符合区间 |
| 2025/Q3 | 5 Nov 2025 | After Market | ±17.0% | -7.05% | 符合区间 |
| 2025/Q2 | 7 Aug 2025 | After Market | ±24.4% | +7.14% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±34.7% | -6.67% | 符合区间 |
| 2024/Q4 | 13 Feb 2025 | After Market | ±27.3% | +25.00% | 符合区间 |
| 2024/Q3 | 7 Nov 2024 | After Market | ±36.4% | -6.12% | 符合区间 |
| 2024/Q2 | 7 Aug 2024 | After Market | ±41.8% | +9.15% | 符合区间 |
| 2024/Q1 | 9 May 2024 | After Market | ±32.5% | +2.91% | 符合区间 |
| 2023/Q4 | 15 Feb 2024 | After Market | ±24.9% | -13.94% | 符合区间 |
| 2023/Q3 | 30 Oct 2023 | After Market | ±24.9% | -13.08% | 符合区间 |
| 2023/Q2 | 2 Aug 2023 | After Market | ±13.9% | -7.99% | 符合区间 |
| 2023/Q1 | 2 May 2023 | After Market | ±14.8% | +3.98% | 符合区间 |
| 2022/Q4 | 16 Feb 2023 | After Market | ±12.9% | -3.24% | 符合区间 |
| 2022/Q3 | 7 Nov 2022 | After Market | ±19.3% | +7.24% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q2, ended Jun 2026
营收$39.01M-1.9% YoY
营业利润-$44.61M+0.5% YoY
净利润-$44.74M-6.7% YoY
摊薄每股收益-$0.14+0.0% YoY
自由现金流-$39.19M-31.0% YoY
经营现金流-$35.58M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率36.4%
营业利润率-102.6%
净利率-82.5%
净资产收益率-929.3%
资产收益率-16.7%
投入资本回报率-17.7%
流动比率4.92
负债/资产比率104.4%
现金及投资$236.87M
总负债$704.76M
净现金（净负债）-$467.88M
暂无评论——快来第一个聊聊 PACB。
登录后参与讨论。